Are you suffering from fever while taking Gloftimab and wondering whether to ignore it or take a prompt action about it? Let us clarify that fever is one of the reasons for the most serious life-theratening condition called Cytokine Release Syndrome (CRS). This article will cover the fever-related doubts from your mind.
What is CRS?
CRS is potential side-effect of Gloftimab. During the process of Gloftimab attacking the target cells, your body’s immune system gets activated and leads to release of proteins called cytokines. This sudden and intense immune response causes the symptoms such as fever, chills, changes in blood pressure and increased heart rate. This reaction is called Cytokine Release Syndrome.
Fever: The warning sign
The earliest warning signs of CRS include fever above 38°C (100.4°F). The next step is to call your doctor or healthcare team to rule out the cause for fever. Never interpret on your own. If you are researching glofitamab injection in India, it is important to understand these warning signs before treatment.
Fever doesn’t always mean CRS
Fever can occur due to other reasons apart from CRS such as serious infections. This fever due to serious infections is associated with symptoms such as chills, weakness, cough, shortness of breath and sore throat. Hence proper diagnosis should be made by doctor.
How to treat fever due to CRS?
Administer the medication to the patients by a healthcare professional in such a way to monitor and manage CRS. Start the therapy according to the step-up dosing schedule to reduce the risk of CRS, administer pretreatment medications, and ensure adequate hydration.
Pretreat all patients with a single 1,000 mg dose of obinutuzumab administered as an intravenous infusion on Cycle 1 Day 1, 7 days prior to initiation of Gloftimab to deplete the circulating and lymphoid tissue B cells. Obinutuzumab should be administered as an intravenous infusion at 50 mg/hour. The rate of infusion can be escalated in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour.
Following pretreatment with obinutuzumab, administer the medication according to the step-up dosing schedule with appropriate premedication, including dexamethasone, to reduce the incidence and severity of CRS.
Patients should be hospitalized during and for 24 hours after completing infusion of the 2.5 mg step-up dose. Patients who experienced any grade CRS during the 2.5 mg step-up dose should be hospitalized during and for 24 hours after completion of the 10 mg step-up dose.
For subsequent doses, patients who experienced Grade ≥ 2 CRS with the previous infusion should be hospitalized during and for 24 hours after the next infusion.
At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold or permanently discontinue the medication based on severity.
Fever is a signal, not a diagnosis. Take the best move by contacting the healthcare team and seek immediate medical attention when the fever is beyond 38°C. Get in touch with 24/7QualityMeds for authentic health content and glofitamab price in India. Information about Columvi injection in India can also help readers understand the medicine and its availability.
